World Heart has reported that it has finalized assignment and exclusive license agreements with LaunchPoint Technologies (LPT) Goleta, California, and Carnegie Mellon University (CMU), Pittsburgh, Pennsylvania for its next-generation minimally invasive blood pump, the MiVAD. The MiVAD is designed to provide partial cardiac support between 2-4 liters per minute to less sick heart failure patients than those served by existing full-support Left Ventricular Assist Devices (LVADs)
The MiVAD design is based on the Pediaflow LVAD design and intellectual property. The PediaFlow LVAD, a miniaturized implantable fully magnetically levitated blood pump, is intended for neonates and has evolved significantly through design and development. The latest version of the PediaFlow pump is approximately the size of a AA battery and was successfully evaluated in a multi-month animal trial this summer.
The Pediaflow LVAD development has been led by the University of Pittsburgh, Pittsburgh, Pennsylvania and has been primarily funded by the National Heart, Lung and Blood Institute with supplemental funding and technology contributions from WorldHeart. WorldHeart, CMU and LPT are members of the development consortium.
The work completed on this device is the foundation for the MiVAD. Additionally, the MiVAD will incorporate existing intellectual property as well as internal and external design features from the Levacor LVAD.
Mr. Alex Martin, CEO of WorldHeart, said: “While WorldHeart continues to focus on the clinical use and commercialization of the Levacor LVAD, these agreements allow WorldHeart to accelerate the development of the MiVAD and related technology in the area of miniaturization of magnetically levitated blood pumps”.
Brad Paden, founder and CEO of LPT, said: “We are pleased that this breakthrough miniaturization technology will be integrated with WorldHeart’s existing and complementary fully magnetically levitated blood pump platform to meet a new, large and promising clinical need”.